Testing a new vitiligo ointment for face and body patches
Part of Skin clinical trials.
This trial tests an ointment called MH004 to see if it helps repigment white patches in people with non-segmental vitiligo (the most common type). It focuses on patches on the face and body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 12 and 75 years old.
- Your vitiligo is the non-segmental type (patches on both sides of the body).
- The white patches on your face cover at least 0.3% of your body surface area.
- You agree to stop all other vitiligo treatments during the study (like steroids, light therapy, or other prescription creams).
- Women who can become pregnant and men with partners who can become pregnant must use reliable birth control during and for 28 days after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called TEV-53408 to see if it can help with vitiligo, a condition that causes white patches on the skin. It may help by restoring skin color, and the study will check how safe and effective it is.
This trial tests a new cream for vitiligo on the face or neck. It aims to see if the cream can help bring color back to white patches.
This study tests a new medicine called FB102 for people with non-segmental vitiligo. It aims to see if the drug is safe and helps restore skin color.
This study tests a new medicine called LY4005130 for non-segmental vitiligo, a skin condition where patches lose pigment (color). The trial aims to see if this drug can help restore skin color and stop the spread of white patches.
This Phase 2 trial tests whether a new drug called D-2570 can help restore skin color in people with non-segmental vitiligo (when white patches appear randomly across the body). The study will track how well the drug works and check if it's safe to use.
This trial tests a new medicine called GR2301, given as an injection, combined with light therapy, to see if it can help people with vitiligo. It aims to improve skin color in affected areas, especially on the face.
Hear when a new Vitiligo trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.